Hepatic gene expression in morbidly obese women: Implications for disease susceptibility

Obesity

Volumn 17, Issue 8, 2009, Pages 1563-1573

  Elam, Marshall B ^a,b   Cowan, George S ^b   Rooney, Robert J ^c   Hiler, M Lloyd ^b   Yellaturu, Chandrahasa R ^b   Deng, Xiong ^b   Howell, George E ^b   Park, Edwards A ^b   Gerling, Ivan C ^a   Patel, Divyan ^c   Corton, J Christopher ^d   Cagen, Lauren M ^b   Wilcox, Henry G ^b   Gandhi, Malay ^b   Bahr, Micheal H ^b   Allan, Micheal C ^b   Wodi, Linus A ^b   Cook, George A ^b   Hughes, Thomas A ^b   Raghow, Rajendra ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Genome Explorations Inc   (United States)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA;

ADULT; ARTICLE; BIOPSY; CELL PROLIFERATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; INFLAMMATION; LIPID METABOLISM; LIVER; METABOLISM; MORBID OBESITY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; BIOPSY; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LIPID METABOLISM; LIVER; OBESITY, MORBID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 67749130653     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.49     Document Type: Article

References (60)

1. Grundy SM. Metabolic complications of obesity. Endocrine 2000;13:155-165.
2. Cottam DR, Mattar SG, Barinas-Mitchell E et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg 2004;14:589-600.
3. Ong JP, Elariny H, Collantes R et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005;15:310-315.
4. Festi D, Colecchia A, Sacco T et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004;5:27-42.
5. Kiewiet RM, Durian MF, van Leersum M, Hesp FL, van Vliet AC. Gallstone formation after weight loss following gastric banding in morbidly obese Dutch patients. Obes Surg 2006;16:592-596.
6. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2005;7:132-140.
7. Wilson JA, Clark JJ. Obesity: impediment to postsurgical wound healing. Adv Skin Wound Care 2004;17:426-435.
8. Printen KJ, Paulk SC, Mason EE. Acute postoperative wound complications after gastric surgery for morbid obesity. Am Surg 1975;41:483-485.
9. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27-S34.
10. Freeman HJ. Risk of gastrointestinal malignancies and mechanisms of cancer development with obesity and its treatment. Best Pract Res Clin Gastroenterol 2004;18:1167-1175.
11. Correa Lima MP, Gomes-da-Silva MH. Colorectal cancer: lifestyle and dietary factors. Nutr Hosp 2005;20:235-241.
12. McTiernan A. Obesity and cancer: the risks, science, and potential management strategies. Oncology (Williston Park) 2005;19:871-881; discussion 881-872, 885-876.
13. Modesitt SC, van Nagell JR Jr. The impact of obesity on the incidence and treatment of gynecologic cancers: a review. Obstet Gynecol Surv 2005;60:683-692.
14. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-644.
15. Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of SOCS-3 in patients with chronic hepatitis C, viral genotype 1 Gut 2006;55:529-535.
16. Nadler ST, Attie AD. Please pass the chips: genomic insights into obesity and diabetes. J Nutr 2001;131:2078-2081.
17. Nadler ST, Stoehr JP, Schueler KL et al. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. PNAS 2000;97:11371-11376.
18. Linder K, Arner P, Flores-Morales A, Tollet-Egnell P, Norstedt G. Differentially expressed genes in visceral or subcutaneous adipose tissue of obese men and women. J Lipid Res 2004;45:148-154.
19. Deng X, Elam MB, Wilcox HG et al. Dietary olive oil and menhaden oil mitigate induction of lipogenesis in hyperinsulinemic corpulent JCR:LA-cp rats: microarray analysis of lipid-related gene expression Endocrinology 2004;145:5847-5861.
20. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. Jama 2004;292:1724-1737.
21. Lockhart DJ, Dong H, Byrne MC et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-1680.
22. Moulin de Moraes CM, Mancini MC, de Melo ME et al. Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg 2005;15:1287-1291.
23. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 2007;17:486-492.
24. Dalen KT, Schoonjans K, Ulven SM et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes 2004;53:1243-1252.
25. Castro-Chavez F, Yechoor VK, Saha PK et al. Coordinated upregulation of oxidative pathways and downregulation of lipid biosynthesis underlie obesity resistance in perilipin knockout mice: a microarray gene expression profile Diabetes 2003;52:2666-2674.
26. Qi L, Shen H, Larson I et al. Gender-specific association of a perilipin gene haplotype with obesity risk in a white population. Obes Res 2004;12: 1758-1765.
27. Stahlberg D, Rudling M, Angelin B et al. Hepatic cholesterol metabolism in human obesity. Hepatology 1997;25:1447-1450.
28. Jakobsson A, Westerberg R, Jacobsson A. Fatty acid elongases in mammals: their regulation and roles in metabolism. Prog Lipid Res 2006;45:237-249.
29. Matsuzaka T, Shimano H, Yahagi N et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007;13:1193-1202.
30. Wang X, Driscoll DM, Morton RE. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem 1999;274:1814-1820.
31. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
32. Lee KW, Lee Y, Kim DS, Kwon HJ. Direct role of NF-kappaB activation in Toll-like receptor-triggered HLA-DRA expression. Eur J Immunol 2006;36:1254-1266.
33. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004;287:G264-G273.
34. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-1061.
35. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994;265:106-109.
36. Djilali-Saiah I, Fakhfakh A, Louafi H et al. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol 2006;45:844-850.
37. Andrade RJ, Lucena MI, Alonso A et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease Hepatology 2004;39:1603-1612.
38. Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 Gut 2006;55:529-535.
39. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006;43:1177-1186.
40. Hanish SI, Petersen RP, Collins BH et al. Obesity predicts increased overall complications following pancreas transplantation. Transplant Proc 2005;37:3564-3566.
41. Kim J, Hammar N, Jakobsson K et al. Obesity and the risk of early and late mortality after coronary artery bypass graft surgery. Am Heart J 2003;146:555-560.
42. Okamoto O, Fujiwara S. Dermatopontin, a novel player in the biology of the extracellular matrix. Connect Tissue Res 2006;47:177-189.
43. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 1999;15:314-322.
44. Wheatcroft SB, Kearney MT, Shah AM et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance Diabetes 2007;56:285-294.
45. Brabant G, Muller G, Horn R et al. Hepatic leptin signaling in obesity. Faseb J 2005;19:1048-1050.
46. Dunn SL, Bjornholm M, Bates SH et al. Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. Mol Endocrinol 2005;19:925-938.
47. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002;26: 1407-1433.
48. Fujishiro M, Gotoh Y, Katagiri H et al. Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes Mol Endocrinol 2003;17:487-497.
49. Landi S, Gemignani F, Moreno V et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer Pharmacogenet Genomics 2005;15:535-546.
50. Ioannides C, Lewis DF. Cytochromes P450 in the bioactivation of chemicals. Curr Top Med Chem 2004;4:1767-1788.
51. Lang T, Klein K, Fischer J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver Pharmacogenetics 2001;11:399-415.
52. Strange RC, Fryer AA. The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC Sci Publ 1999;148: 231-249.
53. Jang SG, Kim IJ, Kang HC et al. GSTT2 promoter polymorphisms and colorectal cancer risk. BMC Cancer 2007;7:16.
54. Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 2005;25:5834-5845.
55. Ellisen LW, Ramsayer KD, Johannessen CM et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002;10:995-1005.
56. Mindnich R, Moller G, Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2004;218:7-20.
57. Chatterjee B, Echchgadda I, Song CS. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol 2005;400:165-191.
58. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004;126:322-342.
59. Slatter JG, Templeton IE, Castle JC et al. Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome Xenobiotica 2006;36:938-962.
60. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 2004;40:1387-1395.